

## Ad hoc News

**Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act  
(Wertpapierhandelsgesetz)**

### **Biofrontera AG closes placement of capital increase**

Leverkusen, Germany, December 16, 2009 – Biofrontera AG announces that the subscription of shares in the anticipated capital increase at a subscription price of 2.50 Euros was closed on December 15, 2009. According to today's assessment 800,000 shares were subscribed.

The 2 million Euro derived from the capital increase are required to reach the operative goals of the company for 2010 and represent an important requirement for the aspired financial independence of the Biofrontera group. Important milestones for the coming year are the market expansion of the medical cosmetic Belixos<sup>®</sup>, recently launched in Germany, and the preparation of the European approval of BF-200 ALA for the treatment of actinic keratosis.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, Germany  
ISIN: DE0006046113, WKN: 604611

Contact:

Anke zur Mühlen

Biofrontera AG

Tel.: +49 (0214) 87 63 222

Fax.: +49 (0214) 87 63 290

E-mail: [a.zurmuehlen@biofrontera.com](mailto:a.zurmuehlen@biofrontera.com)